Product Description
Mechanisms of Action: LOXL2 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: Western America
Company Founding Year: 1987
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Liver Cirrhosis, Alcoholic|Cholangitis, Sclerosing|Adenocarcinoma|Thrombocythemia, Essential|Thrombocytosis|Liver Cirrhosis|Pancreatic Cancer|Myelofibrosis|Hepatitis, Alcoholic|Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias|Polycythemia Vera|Hepatitis C|Colorectal Cancer|Coinfection|Hepatitis A
Phase 1: Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01323933 |
AB0024-101 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2012-03-01 |
2019-03-19 |
Treatments |
|
NCT01362231 |
AB0024-201 | P1 |
Completed |
Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias |
2012-12-01 |
2019-03-19 |
Treatments |
|
2012-002489-11 |
2012-002489-11 | P2 |
Terminated |
Liver Cirrhosis|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2019-01-26 |
2022-03-13 |
Treatments |
|
2012-002488-88 |
2012-002488-88 | P2 |
Completed |
Liver Cirrhosis|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2016-12-29 |
2022-03-13 |
Treatments |
|
NCT01672879 |
NASH | P2 |
Terminated |
Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2016-09-26 |
2019-03-28 |
Primary Completion Date |
|
2012-002473-61 |
2012-002473-61 | P2 |
Completed |
Cholangitis, Sclerosing |
2016-08-24 |
2022-03-13 |
Treatments |
|
NCT01672853 |
GS-US-321-0102 | P2 |
Completed |
Cholangitis, Sclerosing |
2016-08-08 |
2019-10-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT01672866 |
GS-US-321-0105 | P2 |
Terminated |
Fatty Liver, Alcoholic|Liver Cirrhosis, Alcoholic|Non-alcoholic Steatohepatitis |
2016-08-02 |
2019-03-28 |
Treatments |
|
NCT01769196 |
RAINIER | P2 |
Terminated |
Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis |
2016-02-23 |
2019-03-19 |
Treatments |
|
NCT01759511 |
ATLAS | P2 |
Terminated |
Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis |
2016-02-19 |
2019-03-19 |
||
2012-001571-36 |
RAINIER | P2 |
Terminated |
Idiopathic Pulmonary Fibrosis |
2016-01-04 |
2022-03-13 |
Treatments |
|
2011-003754-61 |
2011-003754-61 | P2 |
Terminated |
Adenocarcinoma|Colorectal Cancer |
2015-01-22 |
2022-03-13 |
Treatments |
|
NCT01707472 |
GS-US-321-0107 | P2 |
Completed |
Liver Cirrhosis|Hepatitis C|Coinfection|Hepatitis A |
2014-10-17 |
2025-07-19 |
Primary Endpoints |
|
NCT01479465 |
GS-US-295-0203 | P2 |
Terminated |
Colorectal Cancer|Adenocarcinoma |
2014-10-01 |
2024-11-27 |
Primary Endpoints |
|
NCT01369498 |
AB0024-102 | P2 |
Completed |
Polycythemia Vera|Thrombocytosis|Thrombocythemia, Essential|Myelofibrosis |
2014-06-05 |
2020-07-05 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
2011-003753-26 |
2011-003753-26 | P2 |
Terminated |
Pancreatic Cancer|Adenocarcinoma |
2013-11-14 |
2022-03-13 |
Treatments |
|
NCT01472198 |
GS-US-324-0101 | P2 |
Completed |
Adenocarcinoma|Pancreatic Cancer |
2013-10-01 |
2019-03-19 |
Treatments |
|
NCT01452308 |
GS-US-321-0101 | P2 |
Completed |
Liver Cirrhosis |
2013-01-01 |
2019-03-19 |
Treatments |